RxDoctor Payments DataLook up a doctor →

Brilio Mojares, MD

Cardiovascular Disease · St Clair Shores, MINPI 1952350126

Payments from drug & device makers

$205,438in general payments, 2019–2025

Across 372 payments — averaging $552.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$168K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$10K
  • Boehringer Ingelheim International GmbH$8K
  • Medtronic$3K
  • Penumbra, Inc.$3K
  • Abbott$2K
  • plus $11K from 32 others

What the payments were for

  • Travel & lodging$6,20631%
  • Food & beverage$13,97269%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,438 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$200,861
Medicare patients
751
Services billed
2,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban323$399,548
XareltoRivaroxaban113$137,687
EntrestoSacubitril/Valsartan73$86,865
JardianceEmpagliflozin30$25,949
BrilintaTicagrelor16$14,486
Repatha SureclickEvolocumab16$8,779
Dabigatran EtexilateDabigatran Etexilate Mesylate17$5,807
Metoprolol Succinate303$5,777
Isosorbide Mononitrate ErIsosorbide Mononitrate262$5,750
Losartan Potassium447$5,690
Atorvastatin Calcium320$5,016
Carvedilol373$4,948
Hydralazine Hcl156$3,268
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$2,767
Ranolazine ErRanolazine12$2,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$399,548323 claims
Johnson & JohnsonXarelto$76$137,687113 claims
NovartisEntresto$340$86,86573 claims
Boehringer IngelheimJardiance$268$25,94930 claims
AstraZenecaBrilinta$25$14,48616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in St Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →